Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Official title

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Study identification

NCT ID

NCT01275677

Recruitment status

Completed

Study type

Interventional

Phase

Phase 3

Lead sponsor

National Cancer Institute (NCI)

NIH

Enrollment

3,270 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

Female

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Feb 7, 2011

Primary completion

Jul 30, 2017

Completion

Jun 1, 2025

Last update posted

Jul 13, 2025

2011 – 2025

United States locations

U.S. sites

1259

U.S. states

51

U.S. cities

800

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.